Study · Randomized controlled trial · n = 8 · 2012

5 results

Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome.

Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL

Psychoneuroendocrinology20 Aug 2011Cited by 107 (Europe PMC)

PMID21862226PMCIDPMC3353652DOI10.1016/j.psyneuen.2011.07.020PepBankPUB-21862226

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In males with fragile X syndrome, 24 IU intranasal oxytocin significantly improved eye gaze frequency during a social challenge.
In plain wordsIn males with fragile X syndrome, a 24 IU nasal oxytocin dose improved eye gaze during a social challenge.
Peptide
Oxytocin
Outcome
IncreaseEye gaze frequency during social challenge
Study
n = 8
Comparator
Placebo
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
24 IU · intranasalAs given in this study (human).
Source sentences
Summary
Eye gaze frequency improved significantly in response to the 24 IU OT dose
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT.
Report a problemFND-2186222601
02HumanRandomized controlled trialEfficacy outcome
In males with fragile X syndrome, 48 IU intranasal oxytocin significantly decreased salivary cortisol during a social challenge.
In plain wordsIn males with fragile X syndrome, a 48 IU nasal oxytocin dose lowered saliva cortisol during a social challenge.
Peptide
Oxytocin
Outcome
DecreaseSalivary cortisol during social challenge
Study
n = 8
Comparator
Placebo
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
48 IU · intranasalAs given in this study (human).
Source sentences
Summary
salivary cortisol levels decreased significantly in response to the 48 IU OT dose.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT.
Report a problemFND-2186222602
03HumanRandomized controlled trialEfficacy outcome
In males with fragile X syndrome, oxytocin had no effect on heart rate, although individual data suggested increases in some participants and decreases in others.
In plain wordsIn males with fragile X syndrome, oxytocin did not change heart rate overall; some people went up and others down.
Peptide
Oxytocin
Outcome
No significant changeHeart rate
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
There was no effect of OT on heart rate, RSA or HRV although individual plots of the heart rate data suggested that OT increased heart rate in some participants and decreased heart rate in others.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT.
Report a problemFND-2186222603
04HumanRandomized controlled trialEfficacy outcome
In males with fragile X syndrome, oxytocin had no effect on respiratory sinus arrhythmia.
In plain wordsIn males with fragile X syndrome, oxytocin did not change respiratory sinus arrhythmia, a measure of heart and breathing rhythm.
Peptide
Oxytocin
Outcome
No significant changeRespiratory sinus arrhythmia
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
There was no effect of OT on heart rate, RSA or HRV
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT.
Report a problemFND-2186222604
05HumanRandomized controlled trialEfficacy outcome
In males with fragile X syndrome, oxytocin had no effect on heart rate variability.
In plain wordsIn males with fragile X syndrome, oxytocin did not change heart rate variability.
Peptide
Oxytocin
Outcome
No significant changeHeart rate variability
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
There was no effect of OT on heart rate, RSA or HRV
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT.
Report a problemFND-2186222605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03081832

Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

University Hospital, Toulousen = 34Jan 2017 to Dec 2018

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 30 Jan 2019

CompletedNot applicableNCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

University Hospital, Toulousen = 4028 Nov 2016 to 11 Jan 2019

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 12 Nov 2020

CompletedPhase 2Results postedNCT01254045

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Stanford Universityn = 10Feb 2007 to Jan 2010

Fragile X Syndrome

Trial page ClinicalTrials.govUpdated 18 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.